Latest Medicago Inc. Stories

- Phase II part B confirms results obtained in Phase II part A - - Company's results continue to be amongst the best for influenza vaccine manufacturing technologies - QUEBEC CITY, June 30, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive final results from a Phase II human clinical trial...

- 2011 "Prix Santé" presented by the Armand-Frappier Foundation - - 2011 Genesis Entrepreneurship Award presented by BIOQuebec - QUEBEC CITY, June 22, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announced today that it was named this month both the recipient of the 2011 "Prix Santé" awarded by the...

APPROVED FOR PUBLIC RELEASE, DISTRIBUTION UNLIMITED RALEIGH, NC and QUEBEC CITY, June 21, 2011 /PRNewswire/ - Medicago USA Inc., a wholly owned subsidiary of Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received the third milestone payment of US$5.6 million from the Defense Advanced Research Projects Agency...

- All tested doses were found safe and well-tolerated - - A single dose of 5 µg met the 3 CHMP immunogenicity criteria - QUEBEC CITY, June 8, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive results from a U.S. Phase I human clinical trial with its seasonal influenza vaccine candidate...

QUEBEC CITY, QUEBEC, May 27, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced its operational and financial results for the first quarter ended March 31, 2011. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. "We recently achieved positive phase...

QUEBEC CITY, May 26, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has entered into a research collaboration agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for the development of a plant-based VLP vaccine candidate for the prevention of Ebola. Ebola...

QUEBEC CITY, April 13 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announced today that it was named "Best Early-Stage Vaccine Biotechnology Company" at the recently held World Vaccine Congress in Washington, D.C. Medicago was also a finalist in the "Best Prophylactic Vaccine" category along with Sanofi, GSK,...

QUEBEC CITY, April 6 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has entered into a research collaboration agreement for the development of a non-influenza vaccine candidate with a top 10 global pharmaceutical company. Under the terms of the research collaboration, Medicago will...

QUEBEC CITY, QC, March 30 /PRNewswire-FirstCall/ -  Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced its operational and financial results for the fourth quarter and year ended December 31, 2010. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. Highlights...

-The Company launches the clinical development of its seasonal flu vaccine- QUEBEC CITY, March 21 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the first dose of vaccine has been administered thereby initiating the Company's phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine")...